查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439214

全球老年黄斑部病变(AMD)市场评估:按疾病,药物类型,给药途径,最终用户,分销管道,地区,机会和预测（2017-2031）

Age Related Macular Degeneration Market Assessment, By Disease, By Drug Type, By Route of Administration, By End-user, By Distribution Channel By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5个工作天内

价格

全球老年黄斑部病变（AMD）市场规模将从2023年的101.9亿美元增至2031年的212.2亿美元，预计2024-2031年预测期间内复合年增长率为9.6%。近年来，该市场呈现显着成长，预计在预测期内将进一步扩大。

根据Journal Cureus发表的一篇文章，预计到 2022 年 9 月，将有 2 亿人患有 AMD。到 2040 年，这一数字预计将增加至约 3 亿。年龄相关性黄斑部病变 (AMD) 市场的成长归功于世界各地各个卫生组织和非政府组织不断努力，以提高人们对适当治疗过程和这种疾病影响的认识。Masu。

市场公司加大投资支持市场扩张

老年黄斑部病变（AMD）在世界各地的盛行率不断上升，促使多个市场参与者和研究机构开发治疗方案和早期诊断解决方案来对抗这种疾病。我们正在投资。例如，Adverum Biotechnologies, Inc. 正在开发 Ixoberogene soroparvovec (Ixo-vec) 作为湿性 AMD 的治疗方法。此临床阶段基因治疗候选产品采用专有载体 AAV.7m8。AAV.7m8 在其自身表达盒的控制下携带阿柏西普的编码序列。目前湿性AMD的治疗需要频繁地眼内注射抗VEGF药物，这对护理人员和患者都造成了负担。Adverum 有潜力提供一种经济高效、持久且安全的眼内治疗选择，满足全球视网膜专家、医疗保健系统以及患者及其照护者的需求。一项患者研究表明，Ixoberogene soroparvovec 对湿性 AMD 受试者俱有一致且持续的治疗水平。

人口老化加剧推动市场发展

由于老年人口不断增加，预计预测期内对 AMD 治疗药物的需求将会增加。由于老年人口黄斑部病变的风险较高，预计市场将随着老年人口的增加而扩大。据世界卫生组织 (WHO) 称，到 2030 年，全球六分之一的人口将超过 60 岁。到2050年，全球60岁以上人口将达21亿，80岁以上人口将达4.26亿。

美国疾病管制与预防中心 (CDC) 估计，美国有 730 万人因老年黄斑部病变 (AMD) 而面临视力丧失的高风险，其中 180 万人患有这种疾病。这些因素正在推动黄斑部病变治疗市场的成长。

北美占有很大的市场份额

老年人口的增加、多个市场参与者的存在以及年龄相关性黄斑部病变 (AMD) 患者数量的增加正在支持该地区的市场扩张。据估计，美国约有 2000 万成年人患有某种形式的黄斑部病变。据Canadian Ophthalmological Society称，年龄相关性黄斑部病变 (AMD) 是加拿大失明的主要原因之一，截至 2022 年 2 月，约有 200 万加拿大人受到影响。

会议将透过重点介绍加拿大眼科医生进行的研究来提高人们对不同治疗方法的认识，这些研究致力于创新旨在增强湿性 AMD 治疗的新疗法。我们致力于传播这一讯息。老年黄斑部病变 (AMD) 研究已在多个领域显示出前景。各种新疗法的化学试验正在进行中，旨在增加 AMD 的治疗选择。这些针对老年性黄斑部病变（AMD）治疗方法的持续投资和努力进一步推动了北美老年黄斑部病变（AMD）市场的扩张。

本报告研究和分析了全球年龄相关性黄斑部病变（AMD）市场，提供市场规模和预测、市场动态以及主要参与者的现状和前景。

目录

第一章研究方法论

第二章 专案范围与定义

第3章执行摘要

第四章全球老年黄斑部病变（AMD）市场展望（2017-2031）

  • 市场规模及预测
    • 金额
    • 数量
  • 疾病
    • 湿AMD
    • 干性AMD
    • 其他
  • 药物类型
    • 阿柏西普（Eylea）
    • 雷珠单抗（Lucentis）
    • 贝伐珠单抗（阿瓦斯汀）
    • □加他尼（Macgen）
    • 维替泊芬（维替泊芬）
    • Brolucizumab（Beovu）
    • 补充
    • 其他
  • 给药途径
    • 静脉
    • 玻璃体
  • 最终用户
    • 免疫科医院
    • 专科诊所
    • 门诊手术中心
    • 家庭医疗
    • 其他
  • 分销渠道
    • 医院药房
    • 零售药店
    • 网上药店
  • 区域
    • 北美
    • 南美洲
    • 欧洲
    • 亚太地区
    • 中东/非洲
  • 市场占有率：依公司划分（2023 年）

第5章全球老年黄斑部病变（AMD）市场展望：按地区（2017-2031）

  • 北美
    • 市场规模及预测
    • 疾病
    • 药物类型
    • 给药途径
    • 最终用户
    • 分销渠道
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印度尼西亚
    • 菲律宾
  • 南美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国
    • 南非

第六章 市场测绘（2023）

  • 按疾病分类
  • 依药物类型
  • 按给药途径
  • 按最终用户
  • 按分销渠道
  • 按地区

第七章 宏观环境与产业结构

  • 供需分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第八章市场动态

  • 增长动力
  • 成长限制因素（问题、限制因素）

第九章 监理架构与创新

  • 专利情况
  • 监管审批
  • 创新/新技术

第十章 主要公司情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析（2023 年）
  • 併购/合资（如适用）
  • SWOT分析（5家进入市场的公司）
  • 专利分析（如果适用）

第11章价格分析

第十二章案例研究

第十三章 主要公司展望

  • Pfizer, Inc.
  • Novartis AG
  • Bausch Health Companies Inc.
  • REGENXBIO Inc.
  • F. Hoffmann-La Roche Ltd
  • 4D Molecular Therapeutics
  • Adverum Biotechnologies, Inc.
  • Santen Pharmaceuticals Co.
  • Bayer AG
  • Valent Pharmaceuticals International, Inc.

第十四章 战略建议

第十五章 关于我们公司、免责声明

Product Code: MX11050

Global age related macular degeneration market is projected to witness a CAGR of 9.6% during the forecast period 2024-2031, growing from USD 10.19 billion in 2023 to USD 21.22 billion in 2031F. The market witnessed significant growth in the recent years and is expected to further expand over the forecast period.

Age related macular degeneration (AMD) occur because of damage caused to macula due to aging. Macula is a part of retina, which is responsible for translating the light, that enters the eye, into images. It is responsible for central vision, allowing individuals to view objects directly in front of them. AMD is one of the leading causes of vision loss for older population. The different types of age related macular degeneration include dry AMD and wet AMD. Dry AMD occurs in three stages that include early, intermediate, and late. Wet AMD usually causes faster loss of vision, dry AMD can turn into wet AMD. It occurs due to abnormal blood vessel growth at the back of the eye, which causes damage to macula. According to an article published in Journal Cureus, in September 2022, it is estimated that 200 million people suffer from AMD. The number is projected to increase to roughly 300 million by 2040. The age related macular degeneration market growth can be attributed to the increased initiatives by various health agencies and NGOs across the globe to spread awareness about the adequate course of treatment and impact of the disease.

Increasing Investments by Market Players is Supporting Market Expansion

Owing to increasing prevalence of age-related macular degeneration in various regions across the globe, several market players and research institutions are investing towards the development of treatment options and early diagnostic solutions to combat the disease. For instance, Adverum Biotechnologies, Inc. is developing Ixoberogene soroparvovec (Ixo-vec) for the treatment of wet AMD. The clinical-stage gene therapy product candidate utilizes AAV.7m8, a propriety vector. Under the control of proprietary expression cassette, it carries an aflibercept coding sequence. Current care methods for wet AMD care require frequent anti-VEGF injections in the eyes, causing burden for both caregivers and patients. Adverum believes that Ixoberogene soroparvovec has the potential for providing cost effective, durable, and safe in-office treatment options that will address the requirements of retina specialists and healthcare systems across the globe as well as patients and their caregivers. The study conducted in patients demonstrated consistent and continuous therapeutic levels from Ixoberogene soroparvovec in study subjects with wet AMD.

Growing Prevalence in Aging Population to Boost the Market

The demand for AMD drugs is anticipated to increase over the forecast period, owing to rising aging population. As the risk for macular degeneration amongst the geriatric population is high, the market is expected to grow with the increasing number of older people. According to the World Health Organization, by 2030, 1 in 6 people living across the globe will age 60 and above. By 2050, the world's population aged 60 and above will reach 2.1 billion and by 2050 the number of individuals aging 80 years or older will reach 426 million.

The Centers for Disease Control and Prevention projects that 7.3 million individuals in America are at a heightened risk of loss of vision from age related macular degeneration and 1.8 million people suffer from the disease. These factors are bolstering the growth of the macular degeneration treatment market.

North America to Hold a Significant Share of the Market

The growth of geriatric population, strong presence of several market players, and increasing cases of age-related macular degeneration is supporting the expansion of the market in the region. It is estimated that approximately 20 million adults in the United States suffer from some sort of macular degeneration. As per Canadian Ophthalmological Society, age related macular disorder is one of the leading causes of blindness in Canada and as of February 2022, affects approximately 2 million Canadians.

The society is dedicated towards spreading awareness about the different treatments by highlighting the research conducted by Canadian ophthalmologists that are dedicated towards innovating new therapies that aim at enhancing the treatment for wet AMD. Promising age-related macular degeneration research is being conducted on several fronts. Various chemical trials are underway with novel therapies that aim at enhancing the treatment options for AMD. Such continuous investments and initiatives towards development of therapies for age related macular degeneration are further supporting the expansion of North America age related macular degeneration market.

Wet AMD Anticipated to Hold Significant Market Share

Wet age-related macular degeneration roughly accounts for 10% of cases, however, it results in 90% of cases of legal blindness. This disease is an advanced form of the AMD condition and can cause severe and rapid loss of vision. It occurs due to abnormal growth of blood vessels at the back of the eye, causing damage to macula. The current standard of care to aid the prevention of vision loss progression are anti-vascular endothelial growth factor (VEGF) therapies, however, these therapies require repeated intravitreal injections for the remainder of the patient's life. The highly demanding treatment schedule that requires injections every four to twelve weeks is expected to add to the overall demand in the market. Recently, an ophthalmologist at Mayo Clinic in Minnesota, the United States, performed the first subretinal gene therapy as a potential one-time treatment for wet age related macular degeneration as part of a clinical study of RGX-314.

New Developments in Eylea Injections

Eylea blocks the leakage of fluid caused by abnormal growth of blood vessels on the backside of the eye. In 2024, Molecular Therapeutics, linked their gene therapy to a reduction of wet AMD treatment burden by 90%, encouraging the organization to initiate planning for entry in phase 3 next year. An adeno-associated virus vector is used by 4D-150 for delivering transgenes encoding aflibercept. The aim is to eliminate the requirement for frequent injections of Eylea. In phase 2, 51 wet age-related macular degeneration patients at random, for eight weeks received injections of aflibercept or a shot of one of two doses of 4D-150. The patients on an average received 10 anti-VEGF injections in the previous year. By the twenty-four-week analysis, two-thirds of the patients that were on high dose, were injection free.

Future Market Scenario (2024 - 2031F)

Researchers from Anglia Ruskin University (ARU), have been working on developing a way to grow healthy retinal pigment epithelial (RPE) cells that can remain viable for up to 150 days. Retinal pigment epithelial cells are present outside the neural part of retina. The replacement of retinal pigment epithelial cells is one of the various promising therapeutic options available for effective treatment of age-related macular degeneration. Researchers are actively working on finding effective ways for transplanting these cells in eyes.

Recently Adverum Biotechnologies, Inc. released data from their optic extension study on patients suffering from wet age-related macular degeneration during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) annual meeting. The patients continued to experience long term benefits including reduction in anti-VEGF treatment burden and maintenance of vision.

Key Players Landscape and Outlook

Key participants in the age-related macular degeneration market include Bausch Health Companies Inc., REGENXBIO Inc., F. Hoffmann-La Roche Ltd, 4D Molecular Therapeutics, and Adverum Biotechnologies, Inc. The expansion of the aging population and increasing prevalence of age-related macular degeneration are providing lucrative growth opportunities to the market.

In 2023, Bausch+ Lomb Corporation, a subsidiary of Bausch Health Companies Inc., launched PreserVision AREDS 2 Formula eye vitamins plus coenzyme Q10 that combine the nutrient formula recommended by the NEI to aid in reducing the risk of moderate to advanced AMD progression. The global eye health company is dedicated towards helping their customers to live better lives.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Age-Related Macular Degeneration Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. Disease
    • 4.2.1. Wet AMD
    • 4.2.2. Dry AMD
    • 4.2.3. Others
  • 4.3. Drug Type
    • 4.3.1. Aflibercept (Eylea)
    • 4.3.2. Ranibizumab (Lucentis)
    • 4.3.3. Bevacizumab (Avastin)
    • 4.3.4. Pegaptanib (Macugen)
    • 4.3.5. Verteporfin (Visudyne)
    • 4.3.6. Brolucizumab (Beovu)
    • 4.3.7. Supplements
    • 4.3.8. Others
  • 4.4. Route of Administration
    • 4.4.1. Intravenous
    • 4.4.2. Intravitreal
  • 4.5. End-user
    • 4.5.1. Immunology Hospitals
    • 4.5.2. Specialty Clinics
    • 4.5.3. Ambulatory Surgical Centers
    • 4.5.4. Home Healthcare
    • 4.5.5. Others
  • 4.6. Distribution Channel
    • 4.6.1. Hospital Pharmacies
    • 4.6.2. Retail Pharmacies
    • 4.6.3. Online Pharmacies
  • 4.7. Region
    • 4.7.1. North America
    • 4.7.2. South America
    • 4.7.3. Europe
    • 4.7.4. Asia-Pacific
    • 4.7.5. Middle East & Africa
  • 4.8. By Company Market Share (%), 2023

5. Global Age Related Macular Degeneration Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. Disease
      • 5.1.2.1. Wet AMD
      • 5.1.2.2. Dry AMD
      • 5.1.2.3. Others
    • 5.1.3. Drug Type
      • 5.1.3.1. Aflibercept (Eylea)
      • 5.1.3.2. Ranibizumab (Lucentis)
      • 5.1.3.3. Bevacizumab (Avastin)
      • 5.1.3.4. Pegaptanib (Macugen)
      • 5.1.3.5. Verteporfin (Visudyne)
      • 5.1.3.6. Brolucizumab (Beovu)
      • 5.1.3.7. Supplements
      • 5.1.3.8. Others
    • 5.1.4. Route of Administration
      • 5.1.4.1. Intravenous
      • 5.1.4.2. Intravitreal
    • 5.1.5. End-user
      • 5.1.5.1. Immunology Hospitals
      • 5.1.5.2. Specialty Clinics
      • 5.1.5.3. Ambulatory Surgical Centers
      • 5.1.5.4. Home Healthcare
      • 5.1.5.5. Others
    • 5.1.6. Distribution Channel
      • 5.1.6.1. Hospital Pharmacies
      • 5.1.6.2. Retail Pharmacies
      • 5.1.6.3. Online Pharmacies
    • 5.1.7. United States*
      • 5.1.7.1. Market Size & Forecast
      • 5.1.7.1.1. By Value
      • 5.1.7.1.2. By Volume
      • 5.1.7.2. Disease
      • 5.1.7.2.1. Wet AMD
      • 5.1.7.2.2. Dry AMD
      • 5.1.7.2.3. Others
      • 5.1.7.3. Drug Type
      • 5.1.7.3.1. Aflibercept (Eylea)
      • 5.1.7.3.2. Ranibizumab (Lucentis)
      • 5.1.7.3.3. Bevacizumab (Avastin)
      • 5.1.7.3.4. Pegaptanib (Macugen)
      • 5.1.7.3.5. Verteporfin (Visudyne)
      • 5.1.7.3.6. Brolucizumab (Beovu)
      • 5.1.7.3.7. Supplements
      • 5.1.7.3.8. Others
      • 5.1.7.4. Route of Administration
      • 5.1.7.4.1. Intravenous
      • 5.1.7.4.2. Intravitreal
      • 5.1.7.5. End-user
      • 5.1.7.5.1. Immunology Hospitals
      • 5.1.7.5.2. Specialty Clinics
      • 5.1.7.5.3. Ambulatory Surgical Centers
      • 5.1.7.5.4. Home Healthcare
      • 5.1.7.5.5. Others
      • 5.1.7.6. Distribution Channel
      • 5.1.7.6.1. Hospital Pharmacies
      • 5.1.7.6.2. Retail Pharmacies
      • 5.1.7.6.3. Online Pharmacies
    • 5.1.8. Canada
    • 5.1.9. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Disease
  • 6.2. By Drug Type
  • 6.3. By Route of Administration
  • 6.4. By End-user
  • 6.5. By Distribution Channel
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Pfizer, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Novartis AG
  • 13.3. Bausch Health Companies Inc.
  • 13.4. REGENXBIO Inc.
  • 13.5. F. Hoffmann-La Roche Ltd
  • 13.6. 4D Molecular Therapeutics
  • 13.7. Adverum Biotechnologies, Inc.
  • 13.8. Santen Pharmaceuticals Co.
  • 13.9. Bayer AG
  • 13.10. Valent Pharmaceuticals International, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 4. Global Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 5. Global Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6. Global Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 8. Global Age Related Macular Degeneration Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 11. North America Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 12. North America Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 13. North America Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 14. North America Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 15. North America Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 16. North America Age Related Macular Degeneration Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 19. United States Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 20. United States Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 21. United States Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22. United States Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 23. United States Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 24. Canada Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 26. Canada Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 27. Canada Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 28. Canada Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 29. Canada Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 30. Canada Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 31. Mexico Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 33. Mexico Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 34. Mexico Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 35. Mexico Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 36. Mexico Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 37. Mexico Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 38. Europe Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 40. Europe Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 41. Europe Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 42. Europe Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43. Europe Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 44. Europe Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 45. Europe Age Related Macular Degeneration Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. Germany Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 49. Germany Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 50. Germany Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51. Germany Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 52. Germany Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 53. France Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 55. France Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 56. France Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 57. France Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58. France Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 59. France Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 60. Italy Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. Italy Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 63. Italy Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 64. Italy Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 65. Italy Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 66. Italy Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 67. United Kingdom Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 69. United Kingdom Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 70. United Kingdom Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 71. United Kingdom Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 72. United Kingdom Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 73. United Kingdom Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74. Russia Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 76. Russia Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 77. Russia Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 78. Russia Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 79. Russia Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 80. Russia Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 81. Netherlands Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 83. Netherlands Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 84. Netherlands Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 85. Netherlands Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 86. Netherlands Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 87. Netherlands Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Spain Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Spain Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 91. Spain Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 92. Spain Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93. Spain Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 94. Spain Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95. Turkey Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 97. Turkey Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 98. Turkey Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 99. Turkey Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 100. Turkey Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 101. Turkey Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 102. Poland Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 104. Poland Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 105. Poland Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 106. Poland Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 107. Poland Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 108. Poland Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 109. South America Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. South America Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 112. South America Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 113. South America Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 114. South America Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 115. South America Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116. South America Age Related Macular Degeneration Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Brazil Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 120. Brazil Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 121. Brazil Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 122. Brazil Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 123. Brazil Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 124. Argentina Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 126. Argentina Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 127. Argentina Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 128. Argentina Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 129. Argentina Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 130. Argentina Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131. Asia-Pacific Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 133. Asia-Pacific Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 134. Asia-Pacific Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 135. Asia-Pacific Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 136. Asia-Pacific Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 137. Asia- Pacific Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Asia-Pacific Age Related Macular Degeneration Market Share (%), By Country, 2017-2031F
  • Figure 139. India Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 141. India Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 142. India Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 143. India Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 144. India Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 145. India Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146. China Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 148. China Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 149. China Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 150. China Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151. China Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 152. China Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 153. Japan Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 155. Japan Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 156. Japan Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 157. Japan Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 158. Japan Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 159. Japan Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 160. Australia Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 162. Australia Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 163. Australia Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 164. Australia Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 165. Australia Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 166. Australia Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 167. Vietnam Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. Vietnam Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 170. Vietnam Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 171. Vietnam Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 172. Vietnam Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 173. Vietnam Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. South Korea Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 176. South Korea Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 177. South Korea Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 178. South Korea Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 179. South Korea Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 180. South Korea Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. Indonesia Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. Indonesia Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 184. Indonesia Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 185. Indonesia Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 186. Indonesia Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 187. Indonesia Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 188. Philippines Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 190. Philippines Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 191. Philippines Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 192. Philippines Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 193. Philippines Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 194. Philippines Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 195. Middle East & Africa Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 197. Middle East & Africa Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 198. Middle East & Africa Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 199. Middle East & Africa Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 200. Middle East & Africa Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 201. Middle East & Africa Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 202. Middle East & Africa Age Related Macular Degeneration Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 205. Saudi Arabia Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 206. Saudi Arabia Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 207. Saudi Arabia Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 208. Saudi Arabia Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 209. Saudi Arabia Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 210. UAE Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 212. UAE Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 213. UAE Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 214. UAE Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 215. UAE Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 216. UAE Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 217. South Africa Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 219. South Africa Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 220. South Africa Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 221. South Africa Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 222. South Africa Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 223. South Africa Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 224. By Disease Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023